

The prevalence of diseases leading to blindness in India is extremely high. There are approximately about 15 million blind people in India. The leading causes of blindness in India are Cataract (55%), Refractive errors (19%), Glaucoma (4%) and Corneal Pathology (7%). It is estimated that due to population growth and increased longevity, by 2020 there will be approximately 14 million blind people in India.


Other indications seen include Dry Eye, Anterior Uveitis and Necrotizing Retinosis. Data from our sites suggests that between the years 2003 to 2006 the leading Investigators saw approximately 100,000 patients in this therapeutic area. Many top eye care centers in India are reporting an average overall increase in out patients of 10% –15% per year.

Prevalence for ocular diseases in India is generally similar to global conditions. In some conditions such as vision impairment, the prevalence is significantly higher. Estimated number of people visually impaired in India is approximately 51 million or 18% of the worldwide 285 million.

.Our Sites and Investigators

Our access to the most prominent ophthalmology sites and investigators ensures a large and diverse patient pool along with the most up-to-date lines of medical treatment. We ensure that clinical trials are conducted according to ICH-GCP guidelines meet the highest standards of ethics and integrity.

| Cities | Sites | Investigators |
|--------------|------------|---------------|
| Delhi/ NCR | 11 | 35 |
| Mumbai | 10 | 25 |
| Kolkata | 8 | 20 |
| Bangalore | 9 | 25 |
| Chennai | 9 | 20 |
| Hyderabad | 7 | 15 |
| Pune | 6 | 19 |
| Jaipur | 5 | 12 |
| Ahmedabad | 4 | 15 |
| Nagpur | 4 | 8 |
| Others | 30 | 70 |
| Total | 103 | 264 |



| Indication | Phase |
|------------------------------|-------|
| Bacterial Conjunctivitis | III |
| Uveitis | III |
| Glaucoma | III |
| Corneal Transplant Rejection | II |

Excel Life Sciences Ophthalmology Experience

Excel Life Sciences (ELS) is India's premier clinical trial and site management organization with extensive regulatory and clinical trials expertise. ELS has conducted over 40 studies for FDA submission and has undergone successful FDA and EMEA audits. We lead a network of ICH-GCP compliant investigators across 30 cities. Excel Life Sciences has offices in Boston, Chicago, New Delhi, and Research Triangle Park, NC.

USA +1 – 877 – EXCELOK (877) 392 – 3565 INDIA +91 120 4022 600

E-MAIL excel@excellifesciences.com WEB SITE www.excellifesciences.com